NASDAQ:KALV KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis $27.00 0.00 (0.00%) As of 06/12/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About KalVista Pharmaceuticals Stock (NASDAQ:KALV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KALV alerts:Sign Up Key Stats Today's Range$27.00▼$27.0050-Day Range$19.08▼$27.0052-Week Range$9.83▼$27.00VolumeN/AAverage Volume3.07 million shsMarket Capitalization$1.44 billionP/E RatioN/ADividend YieldN/APrice Target$30.60Consensus RatingHold Company Overview KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions. The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema. These candidates are designed to address unmet needs in rare disease and ophthalmology by improving patient convenience, reducing the burden of disease manifestations and potentially offering long‐lasting therapeutic benefit. Founded in 2010 and headquartered in Cambridge, England, KalVista also maintains operations in Boston, Massachusetts. The company completed its initial public offering on the Nasdaq exchange in 2015 and has since advanced its pipeline through a combination of in‐house research, strategic collaborations and contract manufacturing partnerships. KalVista’s programs target patient populations in North America, Europe and other markets with significant unmet medical need. KalVista is led by President and Chief Executive Officer Anna Berkenstock, PhD, who brings extensive experience in drug discovery, development and corporate strategy. The broader leadership team and board of directors draw on deep expertise in rare disease biology, protease chemistry and clinical development to guide the company’s strategic priorities and global growth.AI Generated. May Contain Errors. Read More KalVista Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreKALV MarketRank™: KalVista Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 513th out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingKalVista Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on no strong buy ratings, 3 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialKalVista Pharmaceuticals has a consensus price target of $30.60, representing about 13.3% upside from its current price of $27.00.Amount of Analyst CoverageKalVista Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about KalVista Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($1.19) to $0.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KalVista Pharmaceuticals is -7.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KalVista Pharmaceuticals is -7.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKalVista Pharmaceuticals has a P/B Ratio of 9.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about KalVista Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.43% of the float of KalVista Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKalVista Pharmaceuticals has a short interest ratio ("days to cover") of 1.97, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in KalVista Pharmaceuticals has recently decreased by 43.23%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKalVista Pharmaceuticals does not currently pay a dividend.Dividend GrowthKalVista Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for KALV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added KalVista Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, KalVista Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $965,493.00 in company stock.Percentage Held by Insiders4.30% of the stock of KalVista Pharmaceuticals is held by insiders.Percentage Held by InstitutionsKalVista Pharmaceuticals has minimal institutional ownership at this time.Read more about KalVista Pharmaceuticals' insider trading history. Receive KALV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KALV Stock News HeadlinesChiesi Group Completes Acquisition of KalVista PharmaceuticalsJune 11, 2026 | businesswire.comKalVista’s Sebetralstat Extension Study Completion Sets Up Key Catalyst for KALV InvestorsJune 5, 2026 | tipranks.com4th of July Chaikin flash saleMarc Chaikin - the 60-year Wall Street veteran who called Nvidia before it surged 45,000% - is running his first-ever 4th of July flash sale through July 6th only. His Power Gauge Report membership comes with a free year of access to his Power Gauge Rating system, a 100% money-back guarantee, and a Hotlist of buy and sell ideas - including a little-known Nvidia partner he calls 'an upgrade to Tesla stock' in the autonomous vehicle race. His tools are used on Bloomberg and Reuters terminals worldwide and have helped investors grow assets by as much as 69,000%. | Chaikin Analytics (Ad)KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000May 31, 2026 | fool.comKalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary AngioedemaMay 28, 2026 | businesswire.comKalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALVMay 19, 2026 | businesswire.comMerger Agreement With Chiesi Puts Strategic Handcuffs on KalVista, Raising Execution and Liquidity RisksMay 16, 2026 | tipranks.comKalVista Pharmaceuticals (KALV) price target decreased by 12.99% to 30.47May 15, 2026 | msn.comSee More Headlines KALV Stock Analysis - Frequently Asked Questions How have KALV shares performed this year? KalVista Pharmaceuticals' stock was trading at $16.15 at the start of the year. Since then, KALV stock has increased by 67.2% and is now trading at $27.00. How were KalVista Pharmaceuticals' earnings last quarter? KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) issued its quarterly earnings results on Thursday, May, 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by $0.05. The specialty pharmaceutical company had revenue of $40.86 million for the quarter, compared to the consensus estimate of $39.03 million. When did KalVista Pharmaceuticals IPO? KalVista Pharmaceuticals (KALV) raised $65 million in an IPO on Thursday, April 9th 2015. The company issued 13,000,000 shares at $5.00 per share. How do I buy shares of KalVista Pharmaceuticals? Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of KalVista Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that KalVista Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Chevron (CVX) and Netflix (NFLX). Company Calendar Last Earnings5/14/2026Today7/05/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 KALV's financial health is in the Green zone, according to TradeSmith. KALV has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KALV CIK1348911 Webwww.kalvista.com Phone857-999-0075Fax866-553-3269Employees100Year Founded2011Price Target and Rating Average Price Target for KalVista Pharmaceuticals$30.60 High Price Target$42.00 Low Price Target$20.00 Potential Upside/Downside+13.3%Consensus RatingHold Rating Score (0-4)2.22 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$109.52 million Net MarginsN/A Pretax Margin-1,290.65% Return on Equity-341.44% Return on Assets-111.94% Debt Debt-to-Equity Ratio8.18 Current Ratio5.17 Quick Ratio5.10 Sales & Book Value Annual Sales$1.43 million Price / Sales1,008.07 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book9.96Miscellaneous Outstanding Shares53,241,000Free Float50,952,000Market Cap$1.44 billion OptionableOptionable Beta-0.12 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:KALV) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredBuy the “unseen winner of the AI race” before July 22Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split...Chaikin Analytics | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredThey proved it worked in '76. Then buried it.In 1976, Chevron, Unocal, and Texaco each confirmed the same energy technology worked - no fuel costs, no carb...Behind the Markets | Sponsored**MARKET CRASH WARNING**A former advisor to the Pentagon and CIA is warning that an 80% Dow drop could arrive within days - and names ...Paradigm Press | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALV Stock Alerts